Rebus Holdings Inc (RBSH)

[Goodmooring]

https://www.sciencedirect.com/science/article/pii/S0753332220301451
Release Date - May 2020
SLs have received considerable attention due to their potent bioactivities, including cancer cell cytotoxicity and antineoplastic efficacy in vivo studies, such as artemisinin [3], parthenolide [4], and thapsigargin [5], which are emerging as promising anticancer leads or prodrugs [8].[color=red][/color]

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6986015/
January 27th, 2020 - One Prodrug - Mipsagargin (G202)
Moreover, one prodrug has reached the stage of clinical phase II trials, where it recently was demonstrated to promote prolonged disease stabilization in patients with advanced hepatocellular carcinoma [59].